A. Ciccarelli, A. Daly, and A. Beckers, The Epidemiology of Prolactinomas, Pituitary, vol.13, issue.9, pp.3-6, 2005.
DOI : 10.1515/JPEM.1995.8.2.79

S. Melmed, F. Casanueva, A. Hoffman, D. Kleinberg, V. Montori et al., Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.2, pp.273-288, 1210.
DOI : 10.1210/jc.2010-1692

O. Dekkers, J. Lagro, P. Burman, J. Jørgensen, J. &. Romijn et al., Recurrence of Hyperprolactinemia after Withdrawal of Dopamine Agonists: Systematic Review and Meta-Analysis, The Journal of Clinical Endocrinology & Metabolism, vol.95, issue.1, pp.43-51, 1210.
DOI : 10.1210/jc.2009-1238

M. Biswas, J. Smith, D. Jadon, P. Mcewan, D. Rees et al., Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas, Clinical Endocrinology, vol.20, issue.1, pp.26-31, 2005.
DOI : 10.1007/BF03348016

P. Iglesias and J. Diez, Macroprolactinoma: a diagnostic and therapeutic update, QJM, vol.16, issue.12, pp.106-495
DOI : 10.1016/j.jocn.2009.05.013
URL : https://academic.oup.com/qjmed/article-pdf/106/6/495/4397959/hcs240.pdf

L. Vroonen, M. Jaffrain-rea, P. Petrossians, G. Tamagno, P. Chanson et al., Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients, European Journal of Endocrinology, vol.95, issue.3, pp.651-662, 2012.
DOI : 10.1210/jc.2009-2095

N. Karavitaki, G. Thanabalasingham, H. Shore, R. Trifanescu, O. Ansorge et al., Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma, Clinical Endocrinology, vol.55, issue.4, pp.524-529, 2006.
DOI : 10.1210/jc.2004-0884

A. Colao and S. Savastano, Medical treatment of prolactinomas, Nature Reviews Endocrinology, vol.73, issue.5, pp.267-278, 2011.
DOI : 10.1111/j.1365-2265.2010.03827.x

M. Molitch, Medical management of prolactin-secreting pituitary adenomas, Pituitary, vol.5, issue.2, pp.55-65, 2002.
DOI : 10.1023/A:1022375429083

N. Pontikides, G. Krassas, E. Nikopoulou, and T. Kaltsas, Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas, Pituitary, vol.2, issue.4, pp.277-281, 2000.
DOI : 10.1023/A:1009913200542

A. Colao, G. Vitale, P. Cappabianca, F. Briganti, A. Ciccarelli et al., Outcome of Cabergoline Treatment in Men with Prolactinoma: Effects of a 24-Month Treatment on Prolactin Levels, Tumor Mass, Recovery of Pituitary Function, and Semen Analysis, The Journal of Clinical Endocrinology & Metabolism, vol.89, issue.4, pp.1704-1711, 2004.
DOI : 10.1210/jc.2003-030979

M. Ono, N. Miki, T. Kawamata, R. Makino, K. Amano et al., Prospective Study of High-Dose Cabergoline Treatment of Prolactinomas in 150 Patients, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.12, pp.4721-4727, 1210.
DOI : 10.1210/jc.2007-2758

F. Casanueva, M. Molitch, J. Schlechte, R. Abs, V. Bonert et al., Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas, Clinical Endocrinology, vol.121, issue.2, pp.265-273, 2006.
DOI : 10.1056/NEJMoa022657
URL : https://hal.archives-ouvertes.fr/hal-00088992

E. Sala, B. Buttoni, P. Malchiodi, E. Verrua, E. Carosi et al., Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas, Journal of Endocrinological Investigation, vol.72, issue.12, pp.39-1377
DOI : 10.1111/j.1365-2265.2009.03657.x

A. Colao, D. Sarno, A. Landi, M. Scavuzzo, F. Cappabianca et al., Macroprolactinoma Shrinkage during Cabergoline Treatment Is Greater in Naive Patients Than in Patients Pretreated with Other Dopamine Agonists: A Prospective Study in 110 Patients, Journal of Clinical Endocrinology & Metabolism, vol.85, issue.6, pp.2247-2252, 2000.
DOI : 10.1210/jc.85.6.2247

M. Lombardi, I. Lupi, M. Cosottini, G. Rossi, L. Manetti et al., Lower Prolactin Levels During Cabergoline Treatment are Associated to Tumor Shrinkage in Prolactin Secreting Pituitary Adenoma, Hormone and Metabolic Research, vol.46, issue.13, pp.939-942, 2014.
DOI : 10.1055/s-0034-1389925

D. Maiter and E. Delgrange, THERAPY OF ENDOCRINE DISEASE: The challenges in managing giant prolactinomas, European Journal of Endocrinology, vol.21, issue.3, pp.170-213
DOI : 10.1007/BF03347299

R. Carija and D. Vucina, Frequency of pituitary tumor apoplexy during treatment of prolactinomas with dopamine agonists: a systematic review. CNS and Neurological Disorders Drug Targets, pp.1012-1014, 2012.

D. Möller-goede, M. Brändle, K. Landau, R. Bernays, and C. Schmid, Pituitary apoplexy: re-evaluation of risk factors for bleeding into pituitary adenomas and impact on outcome, European Journal of Endocrinology, vol.163, issue.3, pp.37-43, 2011.
DOI : 10.1530/EJE-10-0229

X. Zhu, Y. Wang, X. Zhao, C. Jiang, Q. Zhang et al., Incidence of Pituitary Apoplexy and Its Risk Factors in Chinese People: A Database Study of Patients with Pituitary Adenoma, PLOS ONE, vol.43, issue.Suppl 3
DOI : 10.1371/journal.pone.0139088.s001

L. 21-katznelson, E. Laws, S. Melmed, M. Molitch, M. Murad et al., Acromegaly: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.11, pp.99-3933, 1210.
DOI : 10.1210/jc.2014-2700

G. Mazziotti and A. Giustina, Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review, Pituitary, vol.68, issue.8, Suppl 1, pp.60-67, 2010.
DOI : 10.1111/j.1365-2265.2007.03067.x

A. Giustina, G. Mazziotti, V. Torri, M. Spinello, I. Floriani et al., Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly, PLoS ONE, vol.94, issue.8 Suppl 1, 2012736411.
DOI : 10.1371/journal.pone.0036411.s002

F. Castinetti, L. Guignat, P. Giraud, M. Muller, P. Kamenicky et al., Ketoconazole in Cushing's Disease: Is It Worth a Try?, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.5, pp.99-1623, 1210.
DOI : 10.1210/jc.2013-3628

B. Khalil, R. Baudry, C. Guignat, L. Carrasco, C. Guibourdenche et al., Sequential hormonal changes in 21 patients with recurrent Cushing's disease after successful pituitary surgery, European Journal of Endocrinology, vol.151, issue.6, pp.729-737, 2011.
DOI : 10.1530/eje.0.1510727